Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )
Status:
Unknown status
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to asses the long term efficacy, safety and immunogenicity of
ENERCEPTAN® in combination with Methotrexate for the treatment of patients with rheumatoid
arthritis up to 104 weeks
Phase:
Phase 3
Details
Lead Sponsor:
Gema Biotech S.A.
Collaborator:
QUID Quality in Drugs and Devices Latin American Consulting SRL